Skip to content
PreclinicalResearch compoundLimited evidence

CMS‑121

Experimental brain-protective compound: slowed features of aging and Alzheimer's disease in mice, not proven in humans.

NootropicNeuroprotectiveNeuroprotectionMemorynoo.affects.neuroprotectionnoo.affects.memorynoo.affects.anti-inflammatory

Pharmacology

ClassNeuroprotection · Memory
Primary targetFatty acid synthase (FASN) inhibition, reducing lipid peroxidation
Targets3 receptor targets
Half-lifeNot characterized in humans
OnsetNot characterized in humans (animal studies used daily oral dosing)
EvidenceLimited evidence
Affected systemsnoo.affects.neuroprotectionnoo.affects.memorynoo.affects.anti-inflammatory

Contents

DETAILED OVERVIEW

What is CMS-121?

CMS-121 is an experimental compound: a modified, lab-made version of fisetin, a plant substance. It was designed to protect brain cells against damage and aging. It is not an approved medicine anywhere, and it is not a dietary supplement either.

It blocks two enzymes that take part in making fatty acids in cells. As a result, the fats in the cells are damaged less, inflammation in the nervous system falls, and levels of acetyl-CoA rise; this substance plays a part in the cell's energy production and in the activity of memory-related genes. In mice it slowed features of aging and Alzheimer's disease, improved memory and thinking, and showed protective effects in metabolic problems. So far it has mainly been studied in animals and is not proven in humans. There is no human safety data, and its safety in pregnancy and breastfeeding has not been established.

Mechanism

Blocks two fatty acid-making enzymes; raises acetyl-CoA level

Evidence

Preclinical (entering early human trials)

Origin

Fisetin derivative (Salk Institute)

Receptor profile

  • Fatty acid synthase (FASN)Strong
  • Acetyl-CoA carboxylase 1 (ACC1)Moderate
  • Oxytosis / ferroptosis and neuroinflammationModerate

Safety

Side effects, stop signs, contraindications

Side effects · 4

  • No published human safety data: evidence comes almost entirely from mouse and cell-based preclinical studies
  • FASN and ACC1 inhibition could theoretically affect lipid metabolism, but the clinical relevance in humans is unknown
  • Oral bioavailability, tissue distribution and long-term toxicity in humans are uncharacterized
  • Experimental, unapproved drug candidate with an unknown side-effect spectrum

Contraindications · 4

  • Pregnancy and breastfeeding: safety not established, avoid
  • Not an approved medicine: not recommended for human use without clinical supervision
  • Unknown drug interactions with agents affecting lipid metabolism or mitochondrial function
  • Children and adolescents: no data, avoid

Related Nootropics

Same therapeutic category

Studies

Related research and clinical findings

FAQ

FAQ

CMS-121 is an experimental compound engineered from a plant substance called fisetin, designed to protect brain cells from damage and aging. In animal studies it reduced cell-damaging processes and improved memory, but this is an early-stage lab candidate: there's no human data yet, so it shouldn't be treated as an established remedy.

Telegram

Have a question about CMS‑121?

Reach out to us on Telegram for a personalized stack. We'll be happy to help.

Personalized consultation

Want a detailed conversation tailored to your data?

Fill out the prep intake form (your goals, training and health data), and the advisor prepares from it to give genuinely personalized guidance.

Fill out the form

~5–7 min · prep questionnaire · confidential · GDPR-compliant

Structure & chemistry

TypeNootropic
FormulaC20H19NO3
UpdatedOctober 14, 2026
MolekulaX Editorial Team·Source-verified · PubMed · FDA · EMA
Updated: October 14, 2026

The information here is strictly for educational and scientific purposes. It does not replace medical advice or clinical consultation, and it does not encourage illegal substance or pharmaceutical use. Data is sourced. When in doubt, consult your doctor.